News 2020-04-21
Porton Successfully Receives Third US FDA Inspection.
We are proud to announce that Porton’s cGMP-compliant Erlang site located in the Chonqing Metro Region, China passed a 4-day general inspection [April 24-28, 2016] by the US FDA without any Form 483 observations. This is the third successful inspection of our China sites by the US FDA since 2013. Supported by a unified Quality Management System and Corporate Quality Group, Porton’s production sites continue to reliably deliver efficient and high-quality manufacturing solutions across the full life cycle for our valued global customers. Learn how we can help you – contact us today!
Note: Porton is still waiting for FDA’s official written document “EIR” (Establishment Investigation Report) of this Erlang inspection, more information shall be disclosed in compliance with China listed-company disclosure rules accordingly.
Note: Porton is still waiting for FDA’s official written document “EIR” (Establishment Investigation Report) of this Erlang inspection, more information shall be disclosed in compliance with China listed-company disclosure rules accordingly.
Others
More
News 2026-03-22
Porton and Jianxiang Forge Strategic Partnership to Build a New High Ground for Large-scale Peptide Drug Manufacturing
Porton and Jianxiang partner to deliver integrated peptide CDMO services from development to commercial manufacturing, offering scalable, compliant solutions for global clients.
News 2026-03-03
Porton Wins “2025 Best CRO” Award from Daewoong Pharma
Daewoong Pharma highly recognized Porton’s contributions to its drug development through active cooperation based on Porton’s excellent capabilities and expertise.
